Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients.

CONCLUSION: Analysis of the molecular process that leads to decrease in podoplanin expression during neoadjuvant treatment and its regulation may provide novel markers and targets to improve targeted therapy of ESCC.
PMID: 32684738 [PubMed - in process]

Source: World Journal of Gastroenterology - June 20, 2020 Category: Gastroenterology Authors: Warnecke-Eberz U, Plum P, Schweinsberg V, Drebber U, Bruns CJ, Müller DT, Hölscher AH, Bollschweiler E Tags: World J Gastroenterol Source Type: research